




# PHARMACEUTICAL 2023

Arcutis Biotherapeutics Inc.  
Rank 286 of 446





# PHARMACEUTICAL 2023

Arcutis Biotherapeutics Inc.  
Rank 286 of 446

The relative strengths and weaknesses of Arcutis Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Arcutis Biotherapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 29% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	437,406
Cost of Goods Sold	0
Intangible Assets	7,188
Liabilities, Current	37,807
Liabilities, Non-Current	201,886
Other Assets	2,799
Other Compr. Net Income	-831
Other Expenses	754
Other Liabilities	0
Other Net Income	-9,831
Other Revenues	3,686
Property and Equipment	1,881
Research and Development	182,435
Selling, General and Administrative Expense	122,124

Output Variable	Value in 1000 USD
Assets	449,274
Liabilities	239,693
Expenses	305,313
Revenues	3,686
Stockholders Equity	209,581
Net Income	-311,458
Comprehensive Net Income	-311,874
Economic Capital Ratio	14%